Analysts expect Amneal Pharmaceuticals Inc (NYSE:AMRX) to announce $505.78 million in sales for the current quarter, Zacks reports. Six analysts have made estimates for Amneal Pharmaceuticals’ earnings, with the highest sales estimate coming in at $578.10 million and the lowest estimate coming in at $469.80 million. Amneal Pharmaceuticals posted sales of $182.91 million during the same quarter last year, which would indicate a positive year over year growth rate of 176.5%. The business is expected to report its next quarterly earnings results on Thursday, March 7th.
According to Zacks, analysts expect that Amneal Pharmaceuticals will report full year sales of $1.86 billion for the current fiscal year, with estimates ranging from $1.83 billion to $1.95 billion. For the next year, analysts forecast that the company will post sales of $2.05 billion, with estimates ranging from $1.90 billion to $2.31 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Amneal Pharmaceuticals.
Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings data on Wednesday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.01. The firm had revenue of $476.50 million for the quarter, compared to the consensus estimate of $486.01 million. Amneal Pharmaceuticals had a negative net margin of 36.54% and a positive return on equity of 4.98%. The firm’s quarterly revenue was up 87.1% on a year-over-year basis.
Shares of AMRX stock traded down $0.18 during midday trading on Friday, reaching $18.44. 247,272 shares of the company were exchanged, compared to its average volume of 839,504. Amneal Pharmaceuticals has a 12 month low of $13.47 and a 12 month high of $24.48. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of 29.27, a price-to-earnings-growth ratio of 0.90 and a beta of 1.56. The company has a current ratio of 1.91, a quick ratio of 1.26 and a debt-to-equity ratio of 2.92.
Several institutional investors and hedge funds have recently made changes to their positions in AMRX. DekaBank Deutsche Girozentrale acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $101,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $116,000. SG Americas Securities LLC acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $120,000. Neuburgh Advisers LLC acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $123,000. Finally, Great West Life Assurance Co. Can acquired a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $130,000. 32.78% of the stock is currently owned by institutional investors.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Further Reading: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.